Given the documented evidence of DUSP enzymes having pro‐oncogenic activities in various cancers [37, 38], we have investigated the therapeutic potential of BCI, a dual DUSP1/6 inhibitor, across a range of NB cell lines. The gene discussed is DUSP5; the disease is neuroblastoma.